CoChat

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

The epithelial cell adhesion molecule (EpCAM) is often overexpressed in many types of tumors, including colorectal cancer. We sequenced and humanized an EpCAM mouse antibody and used it to develop bispecific EpCAM-CD3 antibodies. Three different designs were used to generate bispecific antibodies such as EpCAM-CD3 CrossMab knob-in-hole, EpCAM ScFv-CD3 ScFv (BITE), and EpCAM ScFv-CD3 ScFv-human Fc designs. These antibody designs showed strong and specific binding to the EpCAM-positive Lovo cell line and T cells, specifically killed EpCAM-positive Lovo cells and not EpCAM-negative Colo741 cells in the presence of T cells, and increased T cells’ IFN-gamma secretion in a dose-dependent manner. In addition, transfection of HEK-293 cells with EpCAM ScFv-CD3 ScFv human Fc mRNA-LNPs resulted in antibody secretion that killed Lovo cells and did not kill EpCAM-negative Colo741 cells. The antibody increased IFN-gamma secretion against Lovo target cells and did not increase it against Colo741 target cells. EpCAM-CD3 hFc mRNA-LNP transfection of several cancer cell lines (A1847, C30, OVCAR-5) also demonstrated functional bispecific antibody secretion. In addition, intratumoral delivery of the EpCAM-CD3 human Fc mRNA-LNPs into OVCAR-5 tumor xenografts combined with intravenous injection of T cells significantly blocked xenograft tumor growth. Thus, EpCAM-CD3 hFc mRNA-LNP delivery to tumor cells shows strong potential for future clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15102860

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Different designs of humanized EpCAM(AUA-1)-CD3 bispecific antibodies. (A) The mouse AUA1 antibody detects EpCAM on different cancer cell surfaces by FACS analysis. This antibody was used for FACS staining with HeLa, Hep3B, Lovo, PC3, and SKOV-3 cells. (B) Humanized regular and bispecific humanized EpCAM ScFv-CD3 Scfv antibodies specifically bound to the EpCAM antigen in Lovo cells and did not bind in Lovo cells with CRISPR/Cas-9 knockout of EpCAM (EpCAM KO). (C) EpCAM-CD3 CrossMab KIH design and SDS gel for reduced (R) and nonreduced (NR) conditions are shown. (D) EpCAM-CD3 (BITE) format design and SDS gel for R and NR conditions are shown. (E) EpCAM-CD3 hFc format design and SDS gel for R and NR conditions are shown.
Figure 1 Different designs of humanized EpCAM(AUA-1)-CD3 bispecific antibodies. (A) The mouse AUA1 antibody detects EpCAM on different cancer cell surfaces by FACS analysis. This antibody was used for FACS staining with HeLa, Hep3B, Lovo, PC3, and SKOV-3 cells. (B) Humanized regular and bispecific humanized EpCAM ScFv-CD3 Scfv antibodies specifically bound to the EpCAM antigen in Lovo cells and did not bind in Lovo cells with CRISPR/Cas-9 knockout of EpCAM (EpCAM KO). (C) EpCAM-CD3 CrossMab KIH design and SDS gel for reduced (R) and nonreduced (NR) conditions are shown. (D) EpCAM-CD3 (BITE) format design and SDS gel for R and NR conditions are shown. (E) EpCAM-CD3 hFc format design and SDS gel for R and NR conditions are shown.CC BY · PubMed Central
Figure 2 EpCAM-CD3 CrossMab KIH antibody specifically binds to EpCAM-positive cells and T cells, kills EpCAM-positive target cells, and induces IFN-gamma secretion with T cells. (A) FACS shows binding of bispecific antibody to EpCAM-positive Lovo cells and to T cells. (B) Real-time cytotoxicity (RTCA) assay demonstrates killing of EpCAM-positive Lovo cells by EpCAM CrossMab KIH-CD3 antibody with T cells, in a dose-dependent manner. (C) EpCAM CrossMab KIH-CD3 antibody induces IFN-gamma secretion by T cells against EpCAM-positive cells. There was no induction of IFN-gamma secretion against EpCAM-negative Colo741 cells. * p < 0.05, Student’s t-test IFN-gamma secretion against Lovo cells versus Colo741 cells.
Figure 2 EpCAM-CD3 CrossMab KIH antibody specifically binds to EpCAM-positive cells and T cells, kills EpCAM-positive target cells, and induces IFN-gamma secretion with T cells. (A) FACS shows binding of bispecific antibody to EpCAM-positive Lovo cells and to T cells. (B) Real-time cytotoxicity (RTCA) assay demonstrates killing of EpCAM-positive Lovo cells by EpCAM CrossMab KIH-CD3 antibody with T cells, in a dose-dependent manner. (C) EpCAM CrossMab KIH-CD3 antibody induces IFN-gamma secretion by T cells against EpCAM-positive cells. There was no induction of IFN-gamma secretion against EpCAM-negative Colo741 cells. * p < 0.05, Student’s t-test IFN-gamma secretion against Lovo cells versus Colo741 cells.CC BY · PubMed Central
Figure 3 EpCAM-CD3 and EpCAM-CD3 human Fc antibodies bind to EpCAM-positive cells and T cells, kill EpCAM-positive target cells, and induce IFN-gamma secretion with T cells. (A) FACS shows binding of EpCAM-CD3 antibody to EpCAM-positive Lovo cells, as well as T cells. (B) RTCA assay demonstrates dose-dependent killing of Lovo target cells by antibody when incubated with T cells. (C) EpCAM-CD3 antibody with T cells induces IFN-gamma secretion against Lovo cells but not against Colo741 cells. (D) FACS shows binding of EpCAM-CD3 human Fc antibody to Lovo and T cells. (E) RTCA assay demonstrates the dose-dependent killing of EpCAM-positive target cells by antibody when incubated with T cells. (F) EpCAM-CD3 hFc antibody with T cells induces IFN-gamma secretion against Lovo cells and not against Colo741 cells. * p < 0.05, Student’s t-test. IFN-gamma secretion increased when the antibody was incubated with T cells against Lovo cells and not against Colo741 cells.
Figure 3 EpCAM-CD3 and EpCAM-CD3 human Fc antibodies bind to EpCAM-positive cells and T cells, kill EpCAM-positive target cells, and induce IFN-gamma secretion with T cells. (A) FACS shows binding of EpCAM-CD3 antibody to EpCAM-positive Lovo cells, as well as T cells. (B) RTCA assay demonstrates dose-dependent killing of Lovo target cells by antibody when incubated with T cells. (C) EpCAM-CD3 antibody with T cells induces IFN-gamma secretion against Lovo cells but not against Colo741 cells. (D) FACS shows binding of EpCAM-CD3 human Fc antibody to Lovo and T cells. (E) RTCA assay demonstrates the dose-dependent killing of EpCAM-positive target cells by antibody when incubated with T cells. (F) EpCAM-CD3 hFc antibody with T cells induces IFN-gamma secretion against Lovo cells and not against Colo741 cells. * p < 0.05, Student’s t-test. IFN-gamma secretion increased when the antibody was incubated with T cells against Lovo cells and not against Colo741 cells.CC BY · PubMed Central
Figure 4 EpCAM-CD3 hFc mRNA-LNP transfection to HEK-293 cells generates antibodies that bind to Lovo and T cells and demonstrates specific killing. (A) FACS of Lovo, Colo741, and T cells is shown with supernatant collected from HEK-293 cells transfected with mRNA-LNPs. (B) RTCA assay of Lovo and Colo741 cells using supernatant at different dilutions collected from mRNA-LNP-transfected HEK-293 cells. RTCA demonstrates dose-dependent killing of target cells by antibody and T cells. As a negative control, supernatant from untransfected HEK-293 cells was used and tested in an RTCA assay at the same dilutions as the supernatant from transfected HEK-293 cells. (C) IFN-gamma secretion by T cells with EpCAM-CD3 hFc supernatant collected after RTCA against Lovo and Colo741 target cells. The secretion of IFN-gamma was significantly higher for Lovo target cells than for Colo741 target cells. * p < 0.05, Student’s t-test, EpCAM-CD3 hFc with T cells against Lovo cells versus the same conditions against Colo741 cells.
Figure 4 EpCAM-CD3 hFc mRNA-LNP transfection to HEK-293 cells generates antibodies that bind to Lovo and T cells and demonstrates specific killing. (A) FACS of Lovo, Colo741, and T cells is shown with supernatant collected from HEK-293 cells transfected with mRNA-LNPs. (B) RTCA assay of Lovo and Colo741 cells using supernatant at different dilutions collected from mRNA-LNP-transfected HEK-293 cells. RTCA demonstrates dose-dependent killing of target cells by antibody and T cells. As a negative control, supernatant from untransfected HEK-293 cells was used and tested in an RTCA assay at the same dilutions as the supernatant from transfected HEK-293 cells. (C) IFN-gamma secretion by T cells with EpCAM-CD3 hFc supernatant collected after RTCA against Lovo and Colo741 target cells. The secretion of IFN-gamma was significantly higher for Lovo target cells than for Colo741 target cells. * p < 0.05, Student’s t-test, EpCAM-CD3 hFc with T cells against Lovo cells versus the same conditions against Colo741 cells.CC BY · PubMed Central
Figure 5 OVCAR-5, A1847, and C30 cancer cell lines secrete functional EpCAM-CD3-hFc antibody after mRNA-LNP transfection. (A) FACS with supernatant collected from EpCAM-CD3 hFc mRNA-LNP transfected OVCAR-5, A1847, and C30 cells shows high binding of secreted antibodies to EpCAM-positive Lovo and T cells and shows no binding to Colo741 cells. (B) RTCA assay shows that supernatant collected 48 h after EpCAM-CD3 hFc mRNA-LNP transfection of OVCAR-5 cells kills target Lovo cells in the presence of T cells and does not kill Colo741 cells under the same conditions. No killing was observed for the supernatant containing the EpCAM-CD3 hFc antibody alone against target cells without T cells. (C) Induction of IFN-gamma secretion by T cells detected in the supernatant collected after RTCA assay (B) for Lovo target cells and not for Colo741 target cells. * p < 0.05, Student’s t-test, IFN-gamma secretion against Lovo cells versus Colo741 cells.
Figure 5 OVCAR-5, A1847, and C30 cancer cell lines secrete functional EpCAM-CD3-hFc antibody after mRNA-LNP transfection. (A) FACS with supernatant collected from EpCAM-CD3 hFc mRNA-LNP transfected OVCAR-5, A1847, and C30 cells shows high binding of secreted antibodies to EpCAM-positive Lovo and T cells and shows no binding to Colo741 cells. (B) RTCA assay shows that supernatant collected 48 h after EpCAM-CD3 hFc mRNA-LNP transfection of OVCAR-5 cells kills target Lovo cells in the presence of T cells and does not kill Colo741 cells under the same conditions. No killing was observed for the supernatant containing the EpCAM-CD3 hFc antibody alone against target cells without T cells. (C) Induction of IFN-gamma secretion by T cells detected in the supernatant collected after RTCA assay (B) for Lovo target cells and not for Colo741 target cells. * p < 0.05, Student’s t-test, IFN-gamma secretion against Lovo cells versus Colo741 cells.CC BY · PubMed Central
Figure 6 EpCAM-CD3 hFc mRNA-LNPs delivered to OVCAR-5 tumors with intravenous injection of T cells significantly decreased OVCAR-5 xenograft tumor growth. (A) The schedule for mRNA-LNP intratumoral (i.t.) injections and three T cell intravenous (i.v.) injections to OVCAR-5 tumor groups. Note: c. marks cellular delivery of EpCAM-CD3-hFc mRNA-LNP pre-mixed with OVCAR-5 cancer cells; i.t. marks intratumoral delivery; i.v. marks intravenous delivery of T cells. (B) EpCAM-CD3 hFc mRNA-LNPs combined with T cells significantly decreased OVCAR-5 xenograft tumor growth. (C) The schedule for mRNA-LNP intratumoral injection and a single injection of T cells i.v. delivered to OVCAR-5 xenograft tumor model. (D) EpCAM-CD3 hFc mRNA-LNPs significantly decreased OVCAR-5 tumor growth combined with a single injection of T cells. (E) Tumor size and weight significantly decreased with EpCAM-CD3-hFc mRNA-LNP and T cell treatment. Images of tumors (left panel) are shown at the end of experiment. Bars with averages of tumor weight are shown in the right panel. For tumor weights: * p < 0.05, EpCAM-CD3 hFc mRNA-LNP group versus PBS and GFP mRNA-LNP groups, Student’s t-test. (F) There was no increase in ALT, AST, amylase, or LDH levels in mouse serum collected at the end of treatment for the EpCAM-CD3-hFc mRNA-LNP group versus the GFP mRNA-LNP group for the OVCAR-5 xenograft tumor model.
Figure 6 EpCAM-CD3 hFc mRNA-LNPs delivered to OVCAR-5 tumors with intravenous injection of T cells significantly decreased OVCAR-5 xenograft tumor growth. (A) The schedule for mRNA-LNP intratumoral (i.t.) injections and three T cell intravenous (i.v.) injections to OVCAR-5 tumor groups. Note: c. marks cellular delivery of EpCAM-CD3-hFc mRNA-LNP pre-mixed with OVCAR-5 cancer cells; i.t. marks intratumoral delivery; i.v. marks intravenous delivery of T cells. (B) EpCAM-CD3 hFc mRNA-LNPs combined with T cells significantly decreased OVCAR-5 xenograft tumor growth. (C) The schedule for mRNA-LNP intratumoral injection and a single injection of T cells i.v. delivered to OVCAR-5 xenograft tumor model. (D) EpCAM-CD3 hFc mRNA-LNPs significantly decreased OVCAR-5 tumor growth combined with a single injection of T cells. (E) Tumor size and weight significantly decreased with EpCAM-CD3-hFc mRNA-LNP and T cell treatment. Images of tumors (left panel) are shown at the end of experiment. Bars with averages of tumor weight are shown in the right panel. For tumor weights: * p < 0.05, EpCAM-CD3 hFc mRNA-LNP group versus PBS and GFP mRNA-LNP groups, Student’s t-test. (F) There was no increase in ALT, AST, amylase, or LDH levels in mouse serum collected at the end of treatment for the EpCAM-CD3-hFc mRNA-LNP group versus the GFP mRNA-LNP group for the OVCAR-5 xenograft tumor model.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 32

Metadata

Authors
Golubovskaya, V., Sienkiewicz, J., Sun, J., Huang, Y., Hu, L., Zhou, H., Harto, H., Xu, S., Berahovich, R., Bodmer, W., & Wu, L.
Affiliations
  • Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA
  • John Radcliffe Hospital (GB)
Corresponding author
  • Golubovskaya, Vita
  • Wu, Lijun
Venue
Cancers
Publisher
MDPI AG
Published
2023-05-22
Volume
15
Issue
10
Pages
2860
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4377239774
Cited by
31
References
32
Citations by year
2026: 10 · 2025: 7 · 2024: 10 · 2023: 4
FWCI
5.13
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Promab Biotechnologies
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
humanized monoclonal antibody, colorectal cancer, tumor cell killing, IFN-gamma secretion, T cell cytotoxicity, intratumoral drug delivery, tumor xenografts, LoVo cells, antibody design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth. https://app.cochat.ai/papers/10.3390/cancers15102860
The paper
Golubovskaya, V., Sienkiewicz, J., Sun, J., Huang, Y., Hu, L., Zhou, H., Harto, H., Xu, S., Berahovich, R., Bodmer, W., & Wu, L. (2023). mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth. Cancers. https://doi.org/10.3390/cancers15102860

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.